216 related articles for article (PubMed ID: 26926369)
1. [The prognostic value of baseline serum free light chain in cardiac amyloidosis].
Zhao L; Tian Z; Fang Q
Zhonghua Nei Ke Za Zhi; 2016 Mar; 55(3):186-90. PubMed ID: 26926369
[TBL] [Abstract][Full Text] [Related]
2. [The prognostic value of baseline serum free light chain in immunoglobulin light-chain cardiac amyloidosis].
Wang LM; Wang TT; Tian Y; Zhao L; Yang XC; Chen WM
Zhonghua Xue Ye Xue Za Zhi; 2020 Jan; 41(1):47-53. PubMed ID: 32023754
[No Abstract] [Full Text] [Related]
3. [The diagnostic and prognostic values of serum free light chain in patients with primary light chain amyloidosis].
Zhang CL; Feng J; Shen KN; Su W; Zhang CL; Huang XF; Cao XX; Zhang L; Zhou DB; Li J
Zhonghua Xue Ye Xue Za Zhi; 2016 Nov; 37(11):942-945. PubMed ID: 27995877
[TBL] [Abstract][Full Text] [Related]
4. AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis.
Dittrich T; Bochtler T; Kimmich C; Becker N; Jauch A; Goldschmidt H; Ho AD; Hegenbart U; Schönland SO
Blood; 2017 Aug; 130(5):632-642. PubMed ID: 28550043
[TBL] [Abstract][Full Text] [Related]
5. The association of serum-free light-chain levels with markers of renal function.
Erdem BK; Davran F; Yilmaz VT; Çetinkaya R; Akbas H
Ren Fail; 2015 Jul; 37(6):1057-60. PubMed ID: 26056734
[TBL] [Abstract][Full Text] [Related]
6. Optimization of Serum Immunoglobulin Free Light Chain Analysis for Subclassification of Cardiac Amyloidosis.
Halushka MK; Eng G; Collins AB; Judge DP; Semigran MJ; Stone JR
J Cardiovasc Transl Res; 2015 Jun; 8(4):264-8. PubMed ID: 25925232
[TBL] [Abstract][Full Text] [Related]
7. [The clinical significance of serum free light chain in primary systemic amyloidosis].
Zhai YP; Song P; Li F; Liu HN; Yu YP; Zhou XG; Shi P; An ZM; Zhou X; Zhang CN
Zhonghua Nei Ke Za Zhi; 2011 May; 50(5):404-7. PubMed ID: 21624224
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients.
García de Veas Silva JL; Bermudo Guitarte C; Menéndez Valladares P; Rojas Noboa JC; Kestler K; Duro Millán R
PLoS One; 2016; 11(11):e0166841. PubMed ID: 27893836
[TBL] [Abstract][Full Text] [Related]
9. Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome.
Milani P; Basset M; Russo F; Foli A; Merlini G; Palladini G
Blood; 2017 Aug; 130(5):625-631. PubMed ID: 28546143
[TBL] [Abstract][Full Text] [Related]
10. Clinical presentation and prognosis of light-chain amyloidosis patients with unmeasurable free light-chain levels.
Qiu Y; Zhang CL; Shen KN; Su W; Feng J; Zhang L; Cao XX; Li J
Ann Hematol; 2018 Dec; 97(12):2465-2470. PubMed ID: 30056579
[TBL] [Abstract][Full Text] [Related]
11. Further stratification of patients with multiple myeloma by International Staging System in combination with ratio of serum free κ to λ light chains.
Xu Y; Sui W; Deng S; An G; Wang Y; Xie Z; Yao H; Zhu G; Zou D; Qi J; Hao M; Zhao Y; Wang J; Chen T; Qiu L
Leuk Lymphoma; 2013 Jan; 54(1):123-32. PubMed ID: 22712834
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of patients with AL amyloidosis and low serum free light chain levels at diagnosis.
Nguyen VP; Rosenberg A; Mendelson LM; Comenzo RL; Varga C; Sanchorawala V
Amyloid; 2018 Sep; 25(3):156-159. PubMed ID: 30032640
[TBL] [Abstract][Full Text] [Related]
13. Functional Cardiac Recovery and Hematologic Response to Chemotherapy in Patients With Light-Chain Amyloidosis (from the Stanford University Amyloidosis Registry).
Tuzovic M; Kobayashi Y; Wheeler M; Barrett C; Liedtke M; Lafayette R; Schrier S; Haddad F; Witteles R
Am J Cardiol; 2017 Oct; 120(8):1381-1386. PubMed ID: 28844519
[TBL] [Abstract][Full Text] [Related]
14. Prognosis of Light Chain Amyloidosis With Preserved LVEF: Added Value of 2D Speckle-Tracking Echocardiography to the Current Prognostic Staging System.
Barros-Gomes S; Williams B; Nhola LF; Grogan M; Maalouf JF; Dispenzieri A; Pellikka PA; Villarraga HR
JACC Cardiovasc Imaging; 2017 Apr; 10(4):398-407. PubMed ID: 27639764
[TBL] [Abstract][Full Text] [Related]
15. Immunoparesis defined by heavy+light chain suppression is a novel marker of long-term outcomes in cardiac AL amyloidosis.
Sachchithanantham S; Berlanga O; Alvi A; Mahmood SA; Lachmann HJ; Gillmore JD; Hawkins PN; Harding S; Wechalekar AD
Br J Haematol; 2017 Nov; 179(4):575-585. PubMed ID: 28990174
[TBL] [Abstract][Full Text] [Related]
16. [Clinical Significance of Serum Free Light Chain and Its κ/λ Ratio in Patients with Multiple Myeloma].
Zhao D; Jiang JQ; Lin L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Aug; 27(4):1173-1178. PubMed ID: 31418375
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the N Latex free light chain assay in the diagnosis and monitoring of AL amyloidosis.
Mollee P; Tate J; Pretorius CJ
Clin Chem Lab Med; 2013 Dec; 51(12):2303-10. PubMed ID: 23934643
[TBL] [Abstract][Full Text] [Related]
18. Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features.
Kumar S; Dispenzieri A; Katzmann JA; Larson DR; Colby CL; Lacy MQ; Hayman SR; Buadi FK; Leung N; Zeldenrust SR; Ramirez-Alvarado M; Clark RJ; Kyle RA; Rajkumar SV; Gertz MA
Blood; 2010 Dec; 116(24):5126-9. PubMed ID: 20798235
[TBL] [Abstract][Full Text] [Related]
19. Robust Reference Intervals for Serum Kappa and Lambda Free Light Chains from a Multi Centre Study Population from Hyderabad, India: Myeloma Diagnostic Implications.
Mohammed N; Chandran PA; Kandregula M; Mattaparthi RD; Gundeti S; Volturi J; Darapuneni R; Raju SB; Dattatreya PS
Asian Pac J Cancer Prev; 2016; 17(5):2605-10. PubMed ID: 27268638
[TBL] [Abstract][Full Text] [Related]
20. [Test of Serum Free Light Chain and Its Clinical Significance in Light Chain Multiple Myeloma].
Song P; An ZM; Zhou XG; Li F; Wang LP; Zhao Q; Yu YP; Zhai YP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1357-61. PubMed ID: 26524037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
